Silicon Valley billionaires are obsessed with 'reprogramming' their bodies for longevity. The first human trial suggests they may be onto something.
Silicon Valley billionaires are pursuing body reprogramming techniques for longevity, and the first human trial indicates these methods may actually work. Life Biosciences released first-in-human data from an ongoing Phase 1 clinical trial evaluating the epigenetic restoration therapy known as ER-100 in optic neuropathies and glaucoma. Researchers and technology figures have long focused on anti-aging interventions, but this study marks a concrete milestone by reaching human trials. Eye cells may have been successfully rejuvenated for the first time in people, bringing cellular reprogramming concepts closer to clinical reality.
Listen to Live Briefing
Real-time synthesized voice briefing ยท Live Feeds Desk
- โ Life Biosciences announced first-in-human data from an ongoing Phase 1 trial evaluating ER-100 in optic neuropathies and glaucoma.
What changed
Life Biosciences announced first-in-human data from an ongoing Phase 1 trial evaluating the epigenetic restoration therapy ER-100 in optic neuropathies and glaucoma.
Live updates
-
First Human Trial Suggests Cellular Rejuvenation Is Possible
Silicon Valley billionaires are pursuing body reprogramming techniques for longevity, and the first human trial indicates these methods may actually work. Life Biosciences released first-in-human data from an ongoing Phase 1 clinical trial evaluating the epigenetic restoration therapy known as ER-100 in optic neuropathies and glaucoma. Researchers and technology figures have long focused on anti-aging interventions, but this study marks a concrete milestone by reaching human trials. Eye cells may have been successfully rejuvenated for the first time in people, bringing cellular reprogramming concepts closer to clinical reality.
Why it matters
Cellular reprogramming seeks to reverse aging processes at the molecular level by restoring the epigenetic instructions of cells. Life Biosciences is leading this clinical evaluation with its ER-100 therapy targeting optic neuropathies. This initial data transitions the longevity field from theoretical interest among wealthy investors into active human clinical testing.
What is confirmed
- Life Biosciences announced first-in-human data from an ongoing Phase 1 trial evaluating ER-100 in optic neuropathies and glaucoma.
Still unconfirmed
- Silicon Valley billionaires are obsessed with reprogramming their bodies for longevity.
What to watch next
- Further results from the ongoing Phase 1 trial of ER-100
- Additional clinical data regarding eye cell rejuvenation in humans
confidence 90%Sources used for this update (13)
- en.wikipedia.org โ Silicon - Wikipedia
- periodic-table.com โ Silicon | History, Uses, Facts, Physical & Chemical...
- periodic-table.rsc.org โ Silicon - Element information, properties and uses | Periodic...
- pubchem.ncbi.nlm.nih.gov โ Silicon | Si (Element) - PubChem
- www.chemistrylearner.com โ Silicon Facts, Symbol, Discovery, Properties, Common Uses
- Business Insider โ Silicon Valley billionaires are obsessed with 'reprogramming' their bodies for longevity. The first human trial suggests they may be onto something.
- Time Magazine โ Eye Cells May Have Been Rejuvenated for the First Time in People
- Life Biosciences โ Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
- Longevity.Technology โ Cellular rejuvenation reaches a human trial
- SuaraGarut.ID โ Life Biosciences Reports Early Results From Human Cell Reprogramming Trial
- Dealroom โ Life Biosciences reports first-in-human Phase 1 data for epigenetic restoration therapy ER-100 in glaucoma
- modrinth.com โ Silicon - Minecraft Mod - Modrinth
Community Sentiment: How do you assess this situation?
Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community